<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992457</url>
  </required_header>
  <id_info>
    <org_study_id>Asem Elfert</org_study_id>
    <nct_id>NCT02992457</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection</brief_title>
  <official_title>Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated
      nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in
      Egypt. For decades the antiviral therapy of chronic HCV infection was based on the
      administration of Interferon(IFN), initially alone and then in combination with Ribavirin
      (RBV), but this regimen was effective in only 50% of patients with genotype 1, with
      significant side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated
      nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in
      Egypt. For decades the antiviral therapy of chronic HCV infection was based on the
      administration ofInterferon(IFN), initially alone and then in combination with Ribavirin
      (RBV), but this regimen was effective in only 50% of patients with genotype 1, with
      significant side effects. The introduction of direct acting antiviral agents, in particular
      sofosbuvir (SOF), has revolutionized the treatment for chronic hepatitis C virus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with sustained virological response.</measure>
    <time_frame>2 months</time_frame>
    <description>The number of patients achieving SVR</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">10000</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sof-Riba</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir ribavirin 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sof- Olysio</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir and simeprevir for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sof- Dacla</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir and Daclatasvir for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Harvony</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir and ledipasvir for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ritaprevir, paritaprevir, ombetasvir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Querevo for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sofosbuvir, daclatasvir, simeprevir,ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg daily.</description>
    <arm_group_label>Sof-Riba</arm_group_label>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <arm_group_label>Sof- Olysio</arm_group_label>
    <arm_group_label>Sof- Dacla</arm_group_label>
    <other_name>sovaldi , mpiviropack</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin 1000-1200 mg daily</description>
    <arm_group_label>Sof-Riba</arm_group_label>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <other_name>Rebetol, Riba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated-interferon alfa-2a</intervention_name>
    <description>Pegylated interferon alfa-2a once weekly for 3 months</description>
    <arm_group_label>Sof- Riba- Pegylated interferon</arm_group_label>
    <other_name>peginteron, pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Olysio once daily.</description>
    <arm_group_label>Sof- Olysio</arm_group_label>
    <other_name>Olysio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Dakla once daily for three months.</description>
    <arm_group_label>Sof- Dacla</arm_group_label>
    <other_name>Daklatasvir, Dakla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritaprevir, paritaprevir, ombetasvir</intervention_name>
    <description>Querevo for three months</description>
    <arm_group_label>Ritaprevir, paritaprevir, ombetasvir</arm_group_label>
    <other_name>querevo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir and Ledipasvir</intervention_name>
    <description>Once daily for three months</description>
    <arm_group_label>Harvony</arm_group_label>
    <other_name>Harvony</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvage therapy</intervention_name>
    <description>three months in repeated treatment failure</description>
    <arm_group_label>Salvage therapy</arm_group_label>
    <other_name>Sofosbuvir,simeprevir, daclatasvir, ribavirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • HCV infection

               -  Adult patients, 18years and older.

        Exclusion Criteria:

          -  • Child score &gt; 12

               -  Severe Renal impairment

               -  Pregnant and lactating women

               -  HCC or other malignant neoplasms

               -  Co-infection with human immunodeficiency virus (HIV)

               -  Co-infection with hepatitis B virus (HBV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asem Elfert, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lobna Abo ALi, Ass Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabry Abou Saif, Ass Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taher Eldemerdash, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hala M Elsabagh, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Elkassas, Lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>Helwan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eslam Esmail, Ass Lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam</last_name>
    <role>Study Director</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanta university hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2016</study_first_submitted>
  <study_first_submitted_qc>December 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

